ReviewUnited European gastroenterology journal2018
Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice.
Review in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Orbital manifestations of inflammatory bowel disease - a systematic review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- The value of fecal calprotectin inFrontiers in physiology · 2022Pooled it
- Recent Trend of Laboratory Tests in Common Gastrointestinal Tract Disorders.Diagnostics (Basel, Switzerland) · 2025Review
- Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease.Journal of gastroenterology · 2025Article
- Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota.Frontiers in cellular and infection microbiology · 2025Review
- Research progress on the diagnostic value of fecal calprotectin in colorectal tumors.Frontiers in medicine · 2025Review
- Assessing anorectal function in patients with recurrent ulcerative colitis.International journal of colorectal disease · 2024Article
- Article
- Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn's disease: two complementary tests.Intestinal research · 2022Article
- Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study.Intestinal research · 2022Article
- Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.Life (Basel, Switzerland) · 2021Review
- Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD.Scientific reports · 2021Observational
- The Addition of Other Fecal Biomarkers Does Not Improve the Diagnostic Accuracy of Immunochemical Fecal Occult Blood Test Alone in a Colorrectal Cancer Screening Cohort.Frontiers in medicine · 2021Article
- Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.United European gastroenterology journal · 2020Article
- Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.Alimentary pharmacology & therapeutics · 2020Article
- Calprotectin in inflammatory bowel disease.Clinica chimica acta; international journal of clinical chemistry · 2020Review
- UEG Guidelines framework to guide clinical practice.United European gastroenterology journal · 2020Article
- Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.Inflammatory bowel diseases · 2020Article
- Ulcerative colitis.Nature reviews. Disease primers · 2020Review
- Serum adropin levels are reduced in patients with inflammatory bowel diseases.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite many publications regarding the role of faecal calprotectin (FC) in inflammatory bowel disease (IBD), clear recommendations for its use in clinical practice are currently lacking in the literature.
aimThe aim of this article is to provide practical guidance for clinicians for the use of FC in the detection and management of patients with IBD.
methodsAll relevant publications were analysed and practical statements were proposed based on a Delphi consensus approach.
resultsDifferent commercial assays have been developed but international standardisation is lacking. FC can help in the diagnosis process of IBD. In IBD, FC can predict response to therapy, detect subclinical inflammation and help to drive treatment decisions to achieve better endoscopic and clinical outcomes. After Crohn's surgery FC can identify patients with early endoscopic recurrence.
conclusionAlthough major therapeutic changes should not be based on FC alone, FC is a valuable tool to optimise the care for IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.